Luye Pharma Of China To Be Sold To Investment Firm For $140 Million
This article was originally published in PharmAsia News
Executive Summary
China’s Luye Pharmaceutical Investment, which owns about 77% of Luve Pharma Group, is about to undergo a change of ownership, with South Korea’s MBK Partners agreeing to sell more than half its shares of the drug maker to three investment firms.